Literature DB >> 4626584

Studies on the purification and characterization of human factor 8.

S L Marchesi, N R Shulman, H R Gralnick.   

Abstract

Factor VIII (antihemophilic globulin) has been prepared from Hyland method IV AHG and cryoprecipitate using limited chymotryptic digestion followed by Sepharose gel filtration. The activity of factor VIII is unaffected by the digestion procedure, while fibrinogen in converted to large noncoagulable fragments. The purified factor VIII has been found to be a macromolecular glycoprotein with a major subunit of 240,000, as shown by sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis. Carbohydrate analysis of factor VIII gave values of 1% sialic acid, 2.8% hexosamine, and 1-2% hexose (mannose, galactose, and fucose). The lipid content was found to be less than 5% of the protein content, and included no detectable phospholipid. The amino acid content is also reported. Immunoelectrophoretic analysis using rabbit antibody to purified factor VIII produced a single precipitin line. The chymotrypsin digestion step facilitates the preparation of factor VIII by reducing the viscosity of fibrinogen in the crude starting material, thereby increasing fivefold the quantity of material which can be processed at one time. It also improves markedly the resolution between factor VIII and fibrinogen on gel filtration.

Entities:  

Mesh:

Substances:

Year:  1972        PMID: 4626584      PMCID: PMC292372          DOI: 10.1172/JCI107022

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  26 in total

1.  Molecular weight estimation of polypeptide chains by electrophoresis in SDS-polyacrylamide gels.

Authors:  A L Shapiro; E Viñuela; J V Maizel
Journal:  Biochem Biophys Res Commun       Date:  1967-09-07       Impact factor: 3.575

2.  Fractions rich in factor VIII.

Authors:  M Blombäck; B Blombäck
Journal:  Bibl Haematol       Date:  1968

Review 3.  On the biological role of glycoproteins.

Authors:  E H Eylar
Journal:  J Theor Biol       Date:  1966-01       Impact factor: 2.691

4.  The potent antihemophilic globulin concentrate derived from a cold insoluble fraction of human plasma: characterization and further data on preparation and clinical trial.

Authors:  E J Hershgold; J G Pool; A R Pappenhagen
Journal:  J Lab Clin Med       Date:  1966-01

5.  Activated coagulation factors: in-vivo and in-vitro studies.

Authors:  J Niemetz; H L Nossel
Journal:  Br J Haematol       Date:  1969-04       Impact factor: 6.998

6.  A semiautomatic one-stage factor 8 assay with a commercially prepared standard.

Authors:  J V Simone; J Vanderheiden; C F Abildgaard
Journal:  J Lab Clin Med       Date:  1967-04

7.  Human fibrinogen of relatively high solubility. Comparative biophysical, biochemical, and biological studies with fibrinogen of lower solubility.

Authors:  M W Mosesson; N Alkjaersig; B Sweet; S Sherry
Journal:  Biochemistry       Date:  1967-10       Impact factor: 3.162

8.  Studies on the purification of antihemophilic factor (factor 8. I. Precipitation of antihemophilic factor by concanavalin A.

Authors:  L Kass; O D Ratnoff; M A Leon
Journal:  J Clin Invest       Date:  1969-02       Impact factor: 14.808

9.  Studies on the purification of antihemophilic factor (factor VIII). II. Separation of partially purified antihemophilic factor by gel filtration of plasma.

Authors:  O D Ratnoff; L Kass; P D Lang
Journal:  J Clin Invest       Date:  1969-05       Impact factor: 14.808

10.  Human antihemophilic factor (AHF) purification: A comparison of two procedures.

Authors:  J P Hurt; R H Wagner; K M Brinkhous
Journal:  Thromb Diath Haemorrh       Date:  1966-05-15
View more
  18 in total

1.  Studies on human antihemophilic factor. Evidence for a covalently linked subunit structure.

Authors:  M E Switzer; P A McKee
Journal:  J Clin Invest       Date:  1976-04       Impact factor: 14.808

Review 2.  Von Willebrand factor-cleaving protease and Upshaw-Schulman syndrome.

Authors:  Yoshihiro Fujimura; Masanori Matsumoto; Hideo Yagi; Akira Yoshioka; Taei Matsui; Koiti Titani
Journal:  Int J Hematol       Date:  2002-01       Impact factor: 2.490

3.  Disulfide bonds and the quaternary structure of factor VIII/von Willebrand factor.

Authors:  R B Counts; S L Paskell; S K Elgee
Journal:  J Clin Invest       Date:  1978-09       Impact factor: 14.808

4.  Factor VIII/von Willebrand factor protein. Galactose a cryptic determinant of von Willebrand factor activity.

Authors:  H R Gralnick
Journal:  J Clin Invest       Date:  1978-08       Impact factor: 14.808

5.  Modification of factor VIII complex properties in patients with liver disease.

Authors:  P Maisonneuve; Y Sultan
Journal:  J Clin Pathol       Date:  1977-03       Impact factor: 3.411

6.  Detection of heterozygotes in both parents of homozygous patients with Von Willebrand's disease.

Authors:  Y Sultan; J Simeon; J P Caen
Journal:  J Clin Pathol       Date:  1975-04       Impact factor: 3.411

7.  Studies on the nature of antihemophilic factor (factor VIII). Further evidence relating the AHF-like antigens in normal and hemophilic plasmas.

Authors:  B Bennett; W B Forman; O D Ratnoff
Journal:  J Clin Invest       Date:  1973-09       Impact factor: 14.808

8.  The subunit structure of normal and hemophilic factor VIII.

Authors:  G A Shapiro; J C Andersen; S V Pizzo; P A McKee
Journal:  J Clin Invest       Date:  1973-09       Impact factor: 14.808

9.  Synthesis of antihemophilic factor antigen by cultured human endothelial cells.

Authors:  E A Jaffe; L W Hoyer; R L Nachman
Journal:  J Clin Invest       Date:  1973-11       Impact factor: 14.808

10.  Factor VIII recombination after dissociation by CaCl12.

Authors:  H A Cooper; T R Griggs; R H Wagner
Journal:  Proc Natl Acad Sci U S A       Date:  1973-08       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.